Kymera appoints Jeremy Chadwick as COO; base salary $480K, equity grants

Kymera Therapeutics, Inc.

Jeremy Chadwick, Ph.D., appointed COO effective May 22, 2023; previously SVP at Takeda.
Chadwick receives $480,000 annual base salary, target bonus 40% of base, plus benefits.
Chadwick granted option for 200,000 shares (4-year vest) and RSUs for 33,333 shares (annual vest).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeremy Chadwick, Ph.D.

Chief Operating Officer

KYMR · Kymera Therapeutics, Inc.

Effective: 2023-05-22
Filed: May 22, 2023, 7:59 PM ET

On May 22, 2023, Kymera Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer effective as of May 22, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeremy Chadwick, Ph.D. was appointed as Chief Operating Officer at Kymera Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On May 22, 2023, Kymera Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer effective as of May 22, 2023.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-150555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.